A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

H&N CS 2026

Feb 21, 2026
Oncology
Presentation

J. Lorch, D. Palmer, P. Neupane, A. Sukari, M. Bonomi, D. Adkins, L. Sun, J. Choe, J. Wade, C. Huynh, R.I. Haddad, E. Cohen, V. Graziano, V. Roudko, V. Rhodes, M.N. Maggart, L. Tovar, P. Doherty, R. Duffy, K. Misiukiewicz

Purpose/Objective(s)
Immune checkpoint inhibitors (ICIs) are standard of care (SOC) treatments for recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). However, accurate and reliable biomarkers to predict therapeutic benefit are inadequate. The PHOENIX study will create a robust multi-omic dataset to uncover novel predictive and prognostic biomarkers and to identify biomarkers of resistance to ICIs. PHOENIX will use a combination of next-generation sequencing, circulating tumor DNA, and high-resolution multi-omics data in order to better understand R/M-HNSCC at the molecular level. PHOENIX aims to identify novel targets to support smarter trial design, benchmark early peripheral response with faster readouts, and to build predictive patient models by integrating imaging, pathology, and spatial data. The discovery of novel biomarkers for ICI efficacy may enable more precise therapy, decrease ineffective and/or toxic treatment, suggest other novel therapeutic strategies, and support the development of novel therapies.

 

Materials/Methods
PHOENIX is a prospective, longitudinal, non-interventional study enrolling up to 500 patients with R/M-HNSCC intended for first-line ICIs either alone or with chemotherapy.

 

• Data / Biospecimens

 

○ Tissue: baseline and progression

 

○ Blood: screening, day 1 of each cycle, progression, x2 follow-up

 

○ Images: all routine assessments per SOC

 

○ Clinical Data: demographics, medical history, treatment, toxicity, outcomes

 

• Multi-Omic Analyses

 

○ Proteomics: image-guided microdissection and mass spectrometry to enable both analyses of tumor tissues collected at baseline and/or progression

 

○ Digital spatial profiling: generate high-resolution, spatially resolved molecular data from tumor tissue comprehensively characterize the tumor immune microenvironment

 

○ Single-cell RNA sequencing: map the T-cell receptor landscape in the tumor and peripheral blood to better understand immune responses and identify ICI benefit markers

 

○ Circulating tumor DNA (ctDNA) dynamics: enable non-invasive genotyping and quantitative assessment of ctDNA as a biomarker of treatment response

 

• Endpoints

 

○ Analysis of correlation between biomarker profiles and clinical endpoints

 

○ Real-world overall survival (rwOS), progression-free survival (rwPFS), time to next treatment (rwTTNT), time to treatment discontinuation (rwTTD)

 

Results
N/A - Trials in Progress Conclusion: PHOENIX (NCT06163534) is a prospective multi-omic biomarker profiling study designed to address critical gaps in the understanding of ICI resistance in R/M-HNSCC. By integrating molecular and real-world clinical data, the study aims to identify novel predictive biomarkers, elucidate mechanisms of treatment response and resistance, and inform future therapeutic strategies for a high-need patient population. The study is open to accrual and to date has accrued 41/500 patients.